Xeris Biopharma Holdings, Inc. XERS Total costs & expenses

Total costs & expenses at other companies

Corcept TherapeuticsCORT

$214.85M+28.1%

Zevra Therapeutics, Inc.ZVRA

$21.05M-13.1%

ANI PharmaceuticalsANIP

$225.58M+14.2%

Rigel PharmaceuticalsRIGL

$46.93M+15.7%

Crinetics PharmaceuticalsCRNX

$151.11M+35.2%

Neurocrine BiosciencesNBIX

——

FAQ

What is Xeris Biopharma Holdings, Inc.'s total costs & expenses?

Xeris Biopharma Holdings, Inc. (XERS) reported total costs & expenses of $86.93M in Q2 2026.

How has Xeris Biopharma Holdings, Inc.'s total costs & expenses changed year-over-year?

Xeris Biopharma Holdings, Inc.'s total costs & expenses increased by 29.6% year-over-year, from $67.06M to $86.93M.

What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total costs & expenses?

Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s total costs & expenses has grown at a 12.8% compound annual growth rate (CAGR), from $164.75M to $266.95M.

What does total costs & expenses mean?

This metric represents the aggregate sum of all operating costs incurred by the company to support its primary business activities, including cost of goods sold, research and development, and selling, general, and administrative expenses. It serves as a comprehensive measure of the resources consumed to generate revenue and maintain corporate operations. Monitoring this figure helps investors evaluate the company's operational efficiency and cost management discipline.